ELII: rVSV Vectored Tri-valent Filovirus Vaccine to Protect Against Aerosol Exposure

Project: Other project

StatusFinished
Effective start/end date6/30/1411/30/17

Funding

  • Profectus BioSciences Incorporated: $1,186,084.29